Her new doctor immediately took action, performing a series of tests and soon discovering what others had missed: Avi had ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85% ...

Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national study of a new type of blood test that screens for several different cancers called multi-cancer detection (MCD) tests ...

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Kenya’s fight against cancer has entered a new phase, driven by technological breakthroughs that promise to transform diagnosis, treatment, and survival rates.

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

ArteraAI Prostate analyzes digital pathology images of a prostate cancer biopsy slide to help clinicians predict long-term outcomes.

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Prostate-bed SBRT post-radical prostectomy is well-tolerated and delivers patient-reported outcomes comparable to CFRT, ...

Prostate cancer focal therapies include cryotherapy, irreversible electroporation ablation (IRE), & high-intensity focused ultrasound (HIFU).